CJC-1295 DAC is a synthetic research peptide derived from growth hormone-releasing hormone (GHRH) and modified with a Drug Affinity Complex (DAC). This structural modification is designed to extend the peptide’s biological persistence, distinguishing it from shorter-acting GHRH analogs and making it an area of laboratory research involving sustained GHRH receptor signaling and the growth hormone axis.

CJC-1295 DAC research has explored its interaction with GHRH receptors located within the anterior pituitary. Researchers have investigated the receptor-mediated mechanisms associated with growth hormone secretion and downstream signaling involving insulin-like growth factor-1 (IGF-1).

Another significant area of CJC-1295 DAC research involves the effect of prolonged peptide exposure on neuroendocrine signaling. Laboratory studies have examined how its extended activity influences growth hormone-related pathways, pituitary signaling, and biological processes associated with the GH/IGF-1 axis.

CJC-1295 DAC is synthetically produced for controlled research applications and is typically supplied as a white, lyophilized powder. It is available here in 10mg formulations for laboratory investigation involving GHRH receptor activity, growth hormone signaling, and related neuroendocrine pathways.